(Q39371837)

11 September 2017

title

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. (English)

1 reference

11 September 2017

0 references

1 reference

Lin Chang

1

1 reference

11 September 2017

Vanessa Z Ameen

2

1 reference

11 September 2017

George E Dukes

3

1 reference

11 September 2017

David J McSorley

4

1 reference

11 September 2017

Eric G Carter

5

1 reference

11 September 2017

Emeran A Mayer

6

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

The American Journal of Gastroenterology

11 September 2017

published in

1 reference

11 September 2017

volume

100

1 reference

11 September 2017

issue

1

1 reference

11 September 2017

page(s)

115-123

1 reference

AGA technical review on irritable bowel syndrome

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

Review article: gender-related differences in functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

Sex differences in the perception of noxious experimental stimuli: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

Sex differences of brain serotonin synthesis in patients with irritable bowel syndrome using alpha-[11C]methyl-L-tryptophan, positron emission tomography and statistical parametric mapping

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

Sex and age differences in the pharmacokinetics of alosetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2005.40365.X

10.1111/J.1572-0241.2005.40365.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference